Designing Novel Epitope Based Vaccine Against Epstein-Barr Virus
Channel: ISCB-SC Webinars
Date: 2021-02-18

Epstein-Barr virus, despite being responsible for causing several life-threatening cancers i.e., nasopharyngeal cancer, Burkitt & Hodgkin lymphomas, there is still no effective vaccine available against it. In this study, the immunoinformatics approach was exploited to design a subunit vaccine against highly virulent strains of the virus. The envelope glycoproteins B, H, and M were chosen, & through some rigorous assessments, the most promising MHC class-I, MHC-class-II, and B cell epitopes were selected. With high antigenic, non-allergenic, non-toxic results, the vaccine is supposed to have no negative reaction on the human body but able to produce a healthy immunogenic response. Codon adaptation & in silico cloning studies were also conducted to design a mass production strategy. Our study reveals the vaccine construct as a potential candidate that must undergo wet-lab based inspections.